ACHI Stock Overview
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Achiko AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.0004 |
| 52 Week High | CHF 0.065 |
| 52 Week Low | CHF 0.0004 |
| Beta | -0.70 |
| 11 Month Change | -66.67% |
| 3 Month Change | -80.00% |
| 1 Year Change | -98.92% |
| 33 Year Change | -99.92% |
| 5 Year Change | n/a |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACHI | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 0.6% |
| 1Y | -98.9% | 105.2% | 5.8% |
Return vs Industry: ACHI underperformed the Swiss Biotechs industry which returned -31.4% over the past year.
Return vs Market: ACHI underperformed the Swiss Market which returned -1.2% over the past year.
Price Volatility
| ACHI volatility | |
|---|---|
| ACHI Average Weekly Movement | 78.5% |
| Biotechs Industry Average Movement | 12.7% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.6% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: ACHI's share price has been volatile over the past 3 months.
Volatility Over Time: ACHI's weekly volatility has increased from 51% to 78% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 10 | Steven Goh | www.achiko.com |
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. The company’s lead product is AptameX, a rapid test that uses DNA aptamers instead of antigens to detect the SARS-CoV-2 virus. It also offers Teman Sehat, a mobile check-in and passport application.
Achiko AG Fundamentals Summary
| ACHI fundamental statistics | |
|---|---|
| Market cap | CHF 58.06k |
| Earnings (TTM) | -CHF 6.18m |
| Revenue (TTM) | CHF 22.18k |
2.6x
P/S Ratio0.0x
P/E RatioIs ACHI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACHI income statement (TTM) | |
|---|---|
| Revenue | US$24.60k |
| Cost of Revenue | US$19.31k |
| Gross Profit | US$5.29k |
| Other Expenses | US$6.86m |
| Earnings | -US$6.86m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | 21.51% |
| Net Profit Margin | -27,885.01% |
| Debt/Equity Ratio | -64.4% |
How did ACHI perform over the long term?
See historical performance and comparison